Bivalirudin during thrombolysis with catheter-directed tPA in a heparin-refractory patient: A case report
| Autor: | Michael U. Callaghan, Katherine Regling, Madhvi Rajpurkar |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Drug Resistance Tissue plasminogen activator Antithrombins Catheterization 03 medical and health sciences 0302 clinical medicine Fibrinolytic Agents Intensive care medicine Bivalirudin Humans Thrombolytic Therapy Thrombus business.industry Heparin Thrombosis Hematology Thrombolysis Hirudins medicine.disease Prognosis Peptide Fragments Recombinant Proteins Surgery Oncology Direct thrombin inhibitor 030220 oncology & carcinogenesis Child Preschool Tissue Plasminogen Activator Pediatrics Perinatology and Child Health business 030215 immunology medicine.drug |
| Zdroj: | Pediatric bloodcancerREFERENCES. 67(2) |
| ISSN: | 1545-5017 |
| Popis: | Venous thromboembolism has increasing significance in hospitalized pediatric patients. Patients who have life-threatening or limb-threatening thrombotic events require thrombolysis in addition to anticoagulation. In patients who show signs of heparin resistance or heparin-induced thrombocytopenia, it is imperative to identify alternative therapeutic options. We present a child in whom bivalirudin was used for systemic anticoagulation during catheter-directed thrombolysis along with tissue plasminogen activator (Alteplase® ) for the treatment of a near-occlusive organ-threatening thrombus. We also review the currently available literature on the use of combination therapy of an intravenous direct thrombin inhibitor with alteplase. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text